What Baxter International Investors Should Keep in Mind

Shares of Medical Instruments & Supplies company Baxter International jumped 2.8% today. With many investors piling into BAX without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

  • Baxter International has moved 9.0% over the last year, and the S&P 500 logged a change of 28.7%

  • BAX has an average analyst rating of hold and is -2.32% away from its mean target price of $44.75 per share

  • Its trailing earnings per share (EPS) is $-0.16

  • Baxter International has a trailing 12 month Price to Earnings (P/E) ratio of -273.2 while the S&P 500 average is 15.97

  • Its forward earnings per share (EPS) is $3.22 and its forward P/E ratio is 13.6

  • The company has a Price to Book (P/B) ratio of 2.64 in contrast to the S&P 500's average ratio of 2.95

  • Baxter International is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08

  • BAX has reported YOY quarterly earnings growth of 33.8% and gross profit margins of 0.4%

  • The company has a free cash flow of $1.7 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter

  • Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.